Biocon Limiteds subsidiary Biocon Biologics has received an Official Action Indicated classification from the U.S. FDA for its insulins manufacturing facility in Malaysia, which may cause delay in product approvals or supplements. The company has submitted a corrective and preventive action plan and believes it will not have a material impact on its commercial products for the U.S. market.